Processa Pharmaceuticals, Inc. (PCSA)
$2.07-$0.05 (-2.37%) Today
Russell Skibsted - OfficerRussell Skibsted - OfficerProcessa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The four NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS11T, also referred to as NGC-Iri, is an analog of SN38, and PCS11T, PCS12852, and PCS499.
https://www.processapharmaceuticals.comSEC filings for PCSA on EDGAR
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 15 | 34,160 | $75K |
| Grant or award | 10 | 285,011 | |
| Option exercise | 10 | 4,824 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
81 Form 4 filings on record, the earliest from Jul 24, 2025, newest first. Filing history page 2 of 3.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Patrick Lin - Officer | Open-market purchase | Common Stock | 1,369 | $2.97 | $4K | |
| Wendy Guy - Officer | Open-market purchase | Common Stock | 1,583 | $2.97 | $5K | |
| Russell Skibsted - Officer | Open-market purchase | Common Stock | 1,984 | $2.97 | $6K | |
| George K. Ng - Officer | Open-market purchase | Common Stock | 1,843 | $2.97 | $5K | |
 Sian Bigora - Officer | Open-market purchase | Common Stock | 1,971 | $2.71 | $5K | |
| David Young - Officer | Open-market purchase | Common Stock | 1,706 | $2.69 | $5K | |
| Russell Skibsted - Officer | Open-market purchase | Common Stock | 2,190 | $2.69 | $6K | |
| George K. Ng - Officer | Open-market purchase | Common Stock | 2,034 | $2.69 | $5K | |
| Patrick Lin - Officer | Open-market purchase | Common Stock | 1,511 | $2.69 | $4K | |
| Wendy Guy - Officer | Open-market purchase | Common Stock | 1,748 | $2.69 | $5K | |
| Sian Bigora - Officer | Open-market purchase | Common Stock | 1,986 | $2.69 | $5K | |
| David Young - Officer | Open-market purchase | Common Stock | 1,545 | $2.97 | $5K | |
| George K. Ng - Officer | Open-market purchase | Common Stock | 1,843 | $2.97 | $5K | |
| Patrick Lin - Officer | Open-market purchase | Common Stock | 1,369 | $2.97 | $4K | |
| Wendy Guy - Officer | Open-market purchase | Common Stock | 1,583 | $2.97 | $5K | |
| Sian Bigora - Officer | Open-market purchase | Common Stock | 1,799 | $2.97 | $5K | |
| Russell Skibsted - Officer | Open-market purchase | Common Stock | 1,984 | $2.97 | $6K | |
| James R. Neal | Open-market purchase | Common Stock | 789 | $2.54 | $2K | |
| David Young - Officer | Open-market purchase | Common Stock | 1,810 | $2.54 | $5K | |
| Russell Skibsted - Officer | Open-market purchase | Common Stock | 2,324 | $2.54 | $6K | |
| Geraldine Pannu | Open-market purchase | Common Stock | 2,072 | $2.54 | $5K | |
| George K. Ng - Officer | Open-market purchase | Common Stock | 2,136 | $2.54 | $5K | |
| Patrick Lin - Officer | Open-market purchase | Common Stock | 1,603 | $2.54 | $4K | |
| Wendy Guy - Officer | Open-market purchase | Common Stock | 1,854 | $2.54 | $5K | |
| Sian Bigora - Officer | Open-market purchase | Common Stock | 2,107 | $2.54 | $5K | |
 Khoso Baluch | Open-market purchase | Common Stock | 2,269 | $2.54 | $6K | |
| David Young - Officer | Option exercise | Common Stock | 49 | $0.00 | - | |
| David Young - Officer | Option exercise | Restricted Stock Units | 49 | $0.00 | - | |
| Patrick Lin - Officer | Option exercise | Common Stock | 193 | $0.00 | - | |
| Patrick Lin - Officer | Option exercise | Common Stock | 193 | $0.00 | - | |
| Wendy Guy - Officer | Option exercise | Common Stock | 193 | $0.00 | - | |
| Wendy Guy - Officer | Option exercise | Restricted Stock Units | 193 | $0.00 | - | |
| Sian Bigora - Officer | Option exercise | Common Stock | 249 | $0.00 | - | |
| Sian Bigora - Officer | Option exercise | Restricted Stock Units | 249 | $0.00 | - |
Processa Pharmaceuticals, Inc. (PCSA) had 29 insider filings in the last 90 days, with the most recent on 2026-08-11. The full record for PCSA runs to 81 Form 4 filings, the earliest from 2025-07-24. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
15 insider purchases of PCSA were filed in the last 90 days, totaling $75K.
No insider sales of PCSA were filed in the last 90 days.
This page tracks PCSA Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add PCSA to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
